Indication
Neuroendocrine Tumor Grade 1
4 clinical trials
4 products
Clinical trial
A Phase 1, First-in-human Clinical Trial of [212Pb] VMT-alpha-NET Using a Forward Dosimetric Planning Technique to Treat Refractory or Relapsed Neuroendocrine TumorsStatus: Active (not recruiting), Estimated PCD: 2026-11-20
Product
VMT-α-NETClinical trial
177Lu-DOTATATE Modified Delivery Based on Individualized DosimetryStatus: Not yet recruiting, Estimated PCD: 2029-01-31
Product
Lutetium Lu 177 dotatateClinical trial
A Phase 0 First-in-human Clinical Trial of [203Pb]VMT-α-NET SPECT/CT for Somatostatin Receptor Imaging of Neuroendocrine TumorsStatus: , Estimated PCD: 2025-09-01
Product
[203Pb]VMT-α-NETClinical trial
Randomized Phase II Trial of Everolimus 5 mg vs 10 mg/Daily for Patients With Advanced Neuroendocrine TumorsStatus: Recruiting, Estimated PCD: 2026-05-20
Product
Everolimus